Roche reports positive Phase II results for petrelintide in obesity: amylin analog advances to late-stage trials
Roche's amylin analog petrelintide shows promising weight loss in Phase II, positioning it alongside cagrilintide as next-generation amylin-based therapeutics move toward the clinic.
Ecnoglutide Phase 3 results published in The Lancet: biased GLP-1 receptor agonist shows significant weight loss in obesity trial
A multicentre randomised Phase 3 trial of ecnoglutide, published in The Lancet, demonstrates the potential of biased GLP-1 receptor agonism as a differentiated approach to obesity treatment.
VK2735 Phase 2 VENTURE trial: Viking Therapeutics' dual GIP/GLP-1 agonist shows up to 14.7% weight loss in 13-week study
The Phase 2 VENTURE trial of VK2735, a subcutaneous dual GIP/GLP-1 receptor agonist from Viking Therapeutics, demonstrated dose-dependent weight loss of up to 14.7% at 13 weeks in adults with obesity. Results were published in a peer-reviewed PubMed-indexed journal, adding to the growing body of evidence for next-generation multi-receptor agonists in obesity treatment.
NICE recommends tirzepatide (Mounjaro) for obesity on the NHS: what researchers need to know about TA1026
NICE TA1026: tirzepatide for obesity — eligibility, review points, and what this UK regulatory milestone means for peptide research.
MHRA warns of pulmonary aspiration risk with GLP-1 and dual GIP/GLP-1 receptor agonists before anaesthesia
UK regulator strengthens guidance on GLP-1 agonists and anaesthesia: what peptide researchers need to know about delayed gastric emptying and aspiration risk.
MHRA warns of very rare NAION risk with semaglutide: UK regulator adds vision-loss precautions to Wegovy, Ozempic and Rybelsus
The UK MHRA has published a Drug Safety Update warning that semaglutide may very rarely be associated with non-arteritic anterior ischaemic optic neuropathy (NAION), a condition that can cause sudden vision loss. The EMA's pharmacovigilance committee is also reviewing the signal.
FDA Pharmacy Compounding Advisory Committee to review BPC-157, TB-500 and thymosin peptides: what peptide researchers need to know
The US FDA's PCAC will evaluate whether BPC-157, TB-500, thymosin alpha-1 and other popular research peptides remain on the 503A bulk substances list — a decision that could reshape the global research peptide supply chain
FDA clarifies compounding policy as GLP-1 shortage formally resolves: what it means for peptide researchers
With the FDA declaring an end to the semaglutide and tirzepatide shortages, compounding pharmacies must cease production. The policy shift has ripple effects for the broader research peptide market.
FDA requests removal of suicidal ideation boxed warning from GLP-1 receptor agonists
After a multi-year review, the US FDA concluded there is no causal link between GLP-1 receptor agonists and suicidal thoughts or behaviours, and has asked manufacturers to remove the boxed warning.
Danuglipron Phase 2b results published: Pfizer's oral GLP-1 shows up to 12.9% weight loss but high discontinuation rates
Pfizer's oral small-molecule GLP-1 receptor agonist danuglipron demonstrated dose-dependent weight loss up to 12.9% in a Phase 2b trial, but nearly 38% of participants discontinued due to adverse events.
CagriSema REDEFINE-1 results: Novo Nordisk's dual amylin/GLP-1 combination achieves 22.7% weight loss in Phase 3
Novo Nordisk's CagriSema (cagrilintide + semaglutide) delivered a 22.7% mean weight reduction in the REDEFINE-1 Phase 3 trial, but fell short of expectations for superiority over semaglutide alone.
SURMOUNT-5: Tirzepatide outperforms semaglutide in first head-to-head obesity trial published in NEJM
Eli Lilly's dual GIP/GLP-1 agonist tirzepatide demonstrated superior weight loss compared to semaglutide in the landmark direct-comparison SURMOUNT-5 trial, results published in the New England Journal of Medicine.
Retatrutide Phase 3 TRIUMPH-1 results: Eli Lilly's triple-agonist delivers powerful weight loss in pivotal obesity trial
Eli Lilly has announced top-line results from the first pivotal Phase 3 trial of retatrutide, a GLP-1/GIP/glucagon triple agonist, in adults with obesity. The drug's mechanism — targeting three incretin pathways simultaneously — positions it as a potential next-generation therapy beyond tirzepatide.
MariTide Phase 2 obesity data presented at ADA 2025: monthly GIP/GLP-1 antagonist-agonist shows sustained weight loss
Amgen's MariTide (maridebart cafraglutide) demonstrated up to 20% weight loss at 52 weeks in a Phase 2 obesity trial, with a durable monthly dosing profile.
Pemvidutide Phase 2b MASH results published in The Lancet: dual GLP-1/glucagon agonist shows fibrosis improvement
The GLP-1/glucagon dual agonist pemvidutide met its primary endpoint in a Phase 2b trial for metabolic dysfunction-associated steatohepatitis, published in The Lancet.
Orforglipron Phase 3 ACHIEVE-1 results published in NEJM: oral GLP-1 agonist matches injectable weight loss
The first Phase 3 data for an oral GLP-1 receptor agonist show 12–15% weight loss at 36 weeks, positioning orforglipron as a potential tablet alternative to injectable semaglutide and tirzepatide.
MHRA tightens guidance on research-peptide labelling
New wording clarifies that "not for human consumption" must appear on the primary label, not just the certificate.